These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Treatment of dissociative symptoms in borderline personality disorder with naltrexone: supplementary comments]. Schmahl C; Bohus M Nervenarzt; 2000 May; 71(5):427. PubMed ID: 10846724 [No Abstract] [Full Text] [Related]
7. Naltrexone for Self-Injury in Borderline Personality With Venlafaxine-Associated Hyponatremia. DeLucia B J Clin Psychopharmacol; 2017 Dec; 37(6):743-745. PubMed ID: 28891834 [No Abstract] [Full Text] [Related]
8. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Zarate CA; Quiroz JA; Singh JB; Denicoff KD; De Jesus G; Luckenbaugh DA; Charney DS; Manji HK Biol Psychiatry; 2005 Feb; 57(4):430-2. PubMed ID: 15705360 [TBL] [Abstract][Full Text] [Related]
9. [Childhood traumatization, dissociation and nonsuicidal self-injurious behavior in borderline personality disorder]. Merza K; Harmatta J; Papp G; Kuritárné Szabó I Orv Hetil; 2017 May; 158(19):740-747. PubMed ID: 28490245 [TBL] [Abstract][Full Text] [Related]
13. [Naltrexone in the treatment of dissociative disorders--reflections with regard to a comprehensive therapeutic concept of borderline disorders]. Bolm T; Piegler T Psychiatr Prax; 2001 Jul; 28(5):214-8. PubMed ID: 11479827 [TBL] [Abstract][Full Text] [Related]
14. [Emotional regulation in aspect of action vs. state orientation, stress and self - injurious behavior among people with borderline personality disorder]. Blasczyk-Schiep S; Rabska E; Jaworska-Andryszewska P; Laso A Pol Merkur Lekarski; 2015 Jun; 38(228):315-9. PubMed ID: 26098649 [TBL] [Abstract][Full Text] [Related]
15. Frontal white matter integrity in borderline personality disorder with self-injurious behavior. Grant JE; Correia S; Brennan-Krohn T; Malloy PF; Laidlaw DH; Schulz SC J Neuropsychiatry Clin Neurosci; 2007; 19(4):383-90. PubMed ID: 18070840 [TBL] [Abstract][Full Text] [Related]
16. The effects of exogenous analgesia in a patient with borderline personality disorder (BPD) and severe self-injurious behaviour. Thürauf NJ; Washeim HA Eur J Pain; 2000; 4(1):107-9. PubMed ID: 10833560 [TBL] [Abstract][Full Text] [Related]
17. The effect of riluzole augmentation in a patient with treatment-resistant obsessive-compulsive disorder, taking two other glutaminergic agents. Mahgoub N; Asemota B; Alexopoulos GS J Neuropsychiatry Clin Neurosci; 2011; 23(2):E24-5. PubMed ID: 21677213 [No Abstract] [Full Text] [Related]
18. Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial. Kulkarni J; Thomas N; Hudaib AR; Gavrilidis E; Grigg J; Tan R; Cheng J; Arnold A; Gurvich C CNS Drugs; 2018 Feb; 32(2):179-187. PubMed ID: 29549516 [TBL] [Abstract][Full Text] [Related]
19. Dialectical behavior therapy for borderline personality disorder: a meta-analysis using mixed-effects modeling. Kliem S; Kröger C; Kosfelder J J Consult Clin Psychol; 2010 Dec; 78(6):936-51. PubMed ID: 21114345 [TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania. Coric V; Kelmendi B; Pittenger C; Wasylink S; Bloch MH; Green J J Clin Psychiatry; 2007 Jan; 68(1):170-1. PubMed ID: 17284151 [No Abstract] [Full Text] [Related] [Next] [New Search]